Developer docs
API playgroundTry for free, no card

Search company profiles

AMELIE

Full company profile

uuid003v878

Namestring
AMELIE
Legal namestring
AMELIE (Anchored Muscle cELIs for IncontinencE)
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative cell therapy, faecal incontinence treatment, tissue engineering scaffolds, autologous muscle cell therapy, clinical research consortium
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1EU Horizon 2020 Funding
TypeLicensing Royalties
Description

AMELIE is a 5-year collaborative research project funded by the European Union's Horizon 2020 Framework Programme under grant agreement No 874807. The project is currently in the research and development phase with no commercial revenue.

amelie-project.eu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AMELIE is developing a regenerative cell therapy that uses a patient's own skeletal muscle-derived cells (ASMDC) attached to biodegradable microcarriers for implantation to repair damaged sphincter muscle in patients suffering from faecal incontinence. The therapy is classified as a combined advanced therapy medicinal product (ATMP) and is currently in pan-European clinical trials, with the first six patients treated by July 2026 across two UK sites.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Clinical trial evaluating reduction in frequency of faecal incontinence episodes through pan-European randomised, double-blind trial
+1 more record
Product overview1 text field

AMELIE (Anchored Muscle cELIs for IncontinencE) is a single, unified regenerative cell therapy product. The therapy involves autologous skeletal muscle-derived cells attached to implantable biodegradable microcarriers, classified as a combined advanced therapy medicinal product (ATMP). The approach enables cells to be implanted while remaining attached to a supportive scaffold, improving cell delivery and engraftment to treat faecal incontinence caused by sphincter injury from childbirth, surgery, or trauma.

Product and service1 record
1AMELIE Autologous Skeletal Muscle-Derived Cell Therapy
CategoryRegenerative Medicine / Cell Therapy
Description

A regenerative cell therapy using a patient's own (autologous) skeletal muscle-derived cells attached to biodegradable microcarriers for implantation to restore sphincter muscle function in patients with faecal incontinence caused by childbirth injury, surgery, or trauma. Classified as a combined advanced therapy medicinal product (ATMP).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Project coordinator. Led by Professor Richard Day, Professor of Regenerative Medicine Technology at UCL. Provides overall project leadership and coordination of the 13-partner consortium across 9 countries.

2Bowel Research UK
Strategic tierCoreTypeStrategic or Co-development Partner
Description

UK's leading specialist bowel cancer and bowel cancer research charity. Designated lead for Dissemination and Communication of research activities. Conducts patient and public involvement activities, survey research, and awareness campaigns.

amelie-project.eu
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partner in the 13-organisation consortium contributing research expertise.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Danish academic partner contributing to the multidisciplinary consortium research.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Danish hospital partner providing clinical research expertise and potentially clinical trial sites.

6PNO Innovation
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Innovation consultancy partner providing expertise in translational development and commercialisation strategy.

amelie-project.eu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site where first patients have been treated using the AMELIE regenerative therapy.

8University Hospital of Wales
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site where patients are being treated using the AMELIE regenerative therapy.

amelie-project.eu
9World Federation of Incontinence and Pelvic Problems (WFIPP)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partner in survey research and public awareness campaigns. Supports World Continence Week initiatives and patient advocacy.

amelie-project.eu
10MASIC Foundation
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

UK charity representing women with obstetric injuries (injuries during childbirth). Disseminates surveys and supports patient recruitment to clinical trials.

amelie-project.eu
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

European patient advocacy organisation contributing to survey research on faecal incontinence.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Pluristem Therapeutics
TypeEmerging player
Description

Cell-therapy developer using placenta-derived adherent stromal cells for muscle injury and inflammatory indications. Comparable to AMELIE as a regenerative cell-therapy platform with musculoskeletal applications, though using allogeneic rather than autologous cells.

TypeDirect peer
Description

Clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and musculoskeletal conditions. Comparable to AMELIE in regenerative cell therapy modality and ATMP/Biologics regulatory pathway, though focused on allogeneic rather than autologous cells.

3TiGenix (acquired by Takeda)
TypeDirect peer
Description

Was the leading European cell therapy company; its lead product darvadstrocel (Cx601) treated complex perianal fistulas in Crohn's disease—a near-adjacent indication to AMELIE's faecal incontinence. Acquired by Takeda in 2018 and represents the most relevant historical commercial template for AMELIE.

TypeBroad incumbent
Description

Sells InterStim sacral nerve stimulation therapy, the incumbent minimally-invasive treatment for faecal incontinence. Represents AMELIE's primary competitive alternative in the clinic; large-cap incumbent with established reimbursement and physician adoption.

TypeEmerging player
Description

Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for cardiac and musculoskeletal indications. Comparable to AMELIE in regenerative cell therapy platform approach and ATMP designation, though focused on cardiac rather than sphincter applications.

TypeBroad incumbent
Description

Cook Medical's regenerative medicine division developing autologous cell therapies for urinary and faecal incontinence. Directly comparable to AMELIE's sphincter-regeneration therapeutic concept and is one of AMELIE's closest functional competitors despite broader corporate portfolio.

TypeEmerging player
Description

Commercial regenerative medicine company selling living-cell-based skin and wound-care therapies (Apligraf, Dermagraft). Comparable to AMELIE in scaffold-based living-cell therapy manufacturing and FDA/ATMP-style approval pathway, though focused on dermal rather than muscular indications.

TypeDirect peer
Description

Developer of RECELL, an autologous cell-based regenerative therapy for skin wounds and burns. Closely comparable to AMELIE in using patient-derived cells attached to a delivery scaffold and pursuing ATMP-style regulatory pathways for regenerative indications.

TypeDirect peer
Description

Commercial-stage autologous cell therapy developer (MACI for cartilage repair, Epicel for burns). Vericel is the most directly comparable US-listed autologous cell-therapy business model, sharing AMELIE's regulatory pathway (ATMP/Biologics) and patient-derived cell manufacturing approach.

10Axonics
TypeEmerging player
Description

Commercial-stage developer of sacral neuromodulation systems (SNM) for faecal and urinary incontinence. Direct competitor to AMELIE in the same indication via a different modality (electrical neuromodulation vs. regenerative cell therapy), and a likely benchmark for physician adoption in the same patient population.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AMELIE

Regenerative Cell Therapyamelie-project.eu

AMELIE firmographics

Firmographics
Name
AMELIE
Legal name
AMELIE (Anchored Muscle cELIs for IncontinencE)
Website
https://amelie-project.eu
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

AMELIE industry classification

Industry
Product category
Regenerative Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative cell therapy
  • Faecal incontinence treatment
  • Tissue engineering scaffolds
  • Autologous muscle cell therapy
  • Clinical research consortium

Where AMELIE is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

AMELIE business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. EU Horizon 2020 Funding: AMELIE is a 5-year collaborative research project funded by the European Union's Horizon 2020 Framework Programme under grant agreement No 874807. The project is currently in the research and development phase with no commercial revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

AMELIE product offering

Product offering

Core offering

AMELIE is developing a regenerative cell therapy that uses a patient's own skeletal muscle-derived cells (ASMDC) attached to biodegradable microcarriers for implantation to repair damaged sphincter muscle in patients suffering from faecal incontinence. The therapy is classified as a combined advanced therapy medicinal product (ATMP) and is currently in pan-European clinical trials, with the first six patients treated by July 2026 across two UK sites.

Product overview

AMELIE (Anchored Muscle cELIs for IncontinencE) is a single, unified regenerative cell therapy product. The therapy involves autologous skeletal muscle-derived cells attached to implantable biodegradable microcarriers, classified as a combined advanced therapy medicinal product (ATMP). The approach enables cells to be implanted while remaining attached to a supportive scaffold, improving cell delivery and engraftment to treat faecal incontinence caused by sphincter injury from childbirth, surgery, or trauma.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMELIE Autologous Skeletal Muscle-Derived Cell Therapy A regenerative cell therapy using a patient's own (autologous) skeletal muscle-derived cells attached to biodegradable microcarriers for implantation to restore sphincter muscle function in patients with faecal incontinence caused by childbirth injury, surgery, or trauma. Classified as a combined advanced therapy medicinal product (ATMP).

Quantifiable outcome

  • Clinical trial evaluating reduction in frequency of faecal incontinence episodes through pan-European randomised, double-blind trial
  • +1 more outcomes

Companies that use AMELIE

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

AMELIE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AMELIE partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

  • University College London (UCL)coreStrategic or Co-development PartnerProject coordinator. Led by Professor Richard Day, Professor of Regenerative Medicine Technology at UCL. Provides overall project leadership and coordination of the 13-partner consortium across 9 countries.
  • Bowel Research UKcoreStrategic or Co-development PartnerUK's leading specialist bowel cancer and bowel cancer research charity. Designated lead for Dissemination and Communication of research activities. Conducts patient and public involvement activities, survey research, and awareness campaigns.
  • Queen Mary UniversitymajorStrategic or Co-development PartnerAcademic partner in the 13-organisation consortium contributing research expertise.
  • Aarhus UniversitymajorStrategic or Co-development PartnerDanish academic partner contributing to the multidisciplinary consortium research.
  • Aarhus HospitalmajorStrategic or Co-development PartnerDanish hospital partner providing clinical research expertise and potentially clinical trial sites.
  • PNO InnovationmajorStrategic or Co-development PartnerInnovation consultancy partner providing expertise in translational development and commercialisation strategy.
  • The Royal London HospitalcoreStrategic or Co-development PartnerClinical trial site where first patients have been treated using the AMELIE regenerative therapy.
  • University Hospital of WalescoreStrategic or Co-development PartnerClinical trial site where patients are being treated using the AMELIE regenerative therapy.
  • World Federation of Incontinence and Pelvic Problems (WFIPP)majorStrategic or Co-development PartnerPartner in survey research and public awareness campaigns. Supports World Continence Week initiatives and patient advocacy.
  • MASIC FoundationsupportingStrategic or Co-development PartnerUK charity representing women with obstetric injuries (injuries during childbirth). Disseminates surveys and supports patient recruitment to clinical trials.
  • Associació per la Incontinència Anal (ASIA)supportingStrategic or Co-development PartnerEuropean patient advocacy organisation contributing to survey research on faecal incontinence.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

AMELIE competitors and assessment

Company assessment

Emerging players

  • Pluristem Therapeutics: Cell-therapy developer using placenta-derived adherent stromal cells for muscle injury and inflammatory indications. Comparable to AMELIE as a regenerative cell-therapy platform with musculoskeletal applications, though using allogeneic rather than autologous cells.
  • Capricor Therapeutics: Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for cardiac and musculoskeletal indications. Comparable to AMELIE in regenerative cell therapy platform approach and ATMP designation, though focused on cardiac rather than sphincter applications.
  • Organogenesis: Commercial regenerative medicine company selling living-cell-based skin and wound-care therapies (Apligraf, Dermagraft). Comparable to AMELIE in scaffold-based living-cell therapy manufacturing and FDA/ATMP-style approval pathway, though focused on dermal rather than muscular indications.
  • Axonics: Commercial-stage developer of sacral neuromodulation systems (SNM) for faecal and urinary incontinence. Direct competitor to AMELIE in the same indication via a different modality (electrical neuromodulation vs. regenerative cell therapy), and a likely benchmark for physician adoption in the same patient population.

Direct peers

  • Mesoblast: Clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and musculoskeletal conditions. Comparable to AMELIE in regenerative cell therapy modality and ATMP/Biologics regulatory pathway, though focused on allogeneic rather than autologous cells.
  • TiGenix (acquired by Takeda): Was the leading European cell therapy company; its lead product darvadstrocel (Cx601) treated complex perianal fistulas in Crohn's disease—a near-adjacent indication to AMELIE's faecal incontinence. Acquired by Takeda in 2018 and represents the most relevant historical commercial template for AMELIE.
  • Avita Medical: Developer of RECELL, an autologous cell-based regenerative therapy for skin wounds and burns. Closely comparable to AMELIE in using patient-derived cells attached to a delivery scaffold and pursuing ATMP-style regulatory pathways for regenerative indications.
  • Vericel: Commercial-stage autologous cell therapy developer (MACI for cartilage repair, Epicel for burns). Vericel is the most directly comparable US-listed autologous cell-therapy business model, sharing AMELIE's regulatory pathway (ATMP/Biologics) and patient-derived cell manufacturing approach.

Broad incumbents

  • Medtronic: Sells InterStim sacral nerve stimulation therapy, the incumbent minimally-invasive treatment for faecal incontinence. Represents AMELIE's primary competitive alternative in the clinic; large-cap incumbent with established reimbursement and physician adoption.
  • Cook Myosite: Cook Medical's regenerative medicine division developing autologous cell therapies for urinary and faecal incontinence. Directly comparable to AMELIE's sphincter-regeneration therapeutic concept and is one of AMELIE's closest functional competitors despite broader corporate portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AMELIE social profiles

Digital presence

AMELIE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AMELIE leadership team

Management profile

Number of profiles

Profiles8 records

AMELIE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AMELIE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMELIE

What does AMELIE do?

AMELIE is developing a regenerative cell therapy that uses a patient's own skeletal muscle-derived cells (ASMDC) attached to biodegradable microcarriers for implantation to repair damaged sphincter muscle in patients suffering from faecal incontinence. The therapy is classified as a combined advanced therapy medicinal product (ATMP) and is currently in pan-European clinical trials, with the first six patients treated by July 2026 across two UK sites.

Is AMELIE a public or private company?

AMELIE is a private company. It is classified as unknown and is currently operating.

When was AMELIE founded?

AMELIE was founded in 2020. It employs 11 to 50 people.

Where is AMELIE based?

AMELIE is headquartered in London, United Kingdom, in the Europe region.

How does AMELIE make money?

One revenue line is on record: EU Horizon 2020 Funding.

Who are AMELIE's main competitors?

Emerging players on record are Pluristem Therapeutics, Capricor Therapeutics, Organogenesis and Axonics. Direct peers are Mesoblast, TiGenix (acquired by Takeda), Avita Medical and Vericel. Broad incumbents are Medtronic and Cook Myosite.

Does AMELIE have an API?

No public API is recorded for AMELIE.

What industry is AMELIE in?

AMELIE's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales